A Phase 1, Open-Label, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ASLAN004 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2018
At a glance
- Drugs ASLAN-004 (Primary) ; ASLAN-004 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; First in man
- Sponsors ASLAN Pharmaceuticals
- 17 Oct 2018 According to an ASLAN Pharmaceuticals media release, the company today announced the enrolment of the first subject and the single ascending dose study is expected to complete in the first half of 2019.
- 17 Oct 2018 Status changed from planning to recruiting, according to an ASLAN Pharmaceuticals media release.
- 06 Jul 2018 New trial record